Connection
David Kao to Cytochrome P-450 CYP2C19
This is a "connection" page, showing publications David Kao has written about Cytochrome P-450 CYP2C19.
|
|
Connection Strength |
|
 |
|
 |
|
0.155 |
|
|
|
-
Anderson HD, Thant TM, Kao DP, Crooks KR, Mendola ND, Aquilante CL. Pharmacogenetic testing among patients with depression in a US managed care population. Clin Transl Sci. 2022 07; 15(7):1644-1653.
Score: 0.056
-
Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Netw Open. 2020 12 01; 3(12):e2029411.
Score: 0.051
-
Aquilante CL, Kao DP, Trinkley KE, Lin CT, Crooks KR, Hearst EC, Hess SJ, Kudron EL, Lee YM, Liko I, Lowery J, Mathias RA, Monte AA, Rafaels N, Rioth MJ, Roberts ER, Taylor MR, Williamson C, Barnes KC. Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience. Pharmacogenomics. 2020 04; 21(6):375-386.
Score: 0.048
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|